Journal
JCO PRECISION ONCOLOGY
Volume 5, Issue -, Pages 432-441Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/PO.20.00395
Keywords
-
Categories
Funding
- Boston Biomedical,
- miRNA Therapeutics
- Senhwa Biosciences
- MedImmune
- BiolineRx
- Agios
- Halozyme
- Celgene
- Threshold Pharmaceuticals
- Toray Industries
- Dicerna
- Sillajen
- Eisai
- Taiho Pharmaceutical
- EMD Serono
- Isis Pharmaceuticals
- Incyte
- Sun Biopharma
- ARIAD
- ImClone Systems
- QED Therapeutics
- Puma Biotechnology
- Adaptimmune
- Merck Serono
- RedHill Biopharma
- Basilea
Ask authors/readers for more resources
Studies on virus-based cancer treatment show limited success with monotherapy but genetic engineering offers potential in designing complementary therapies to enhance immune response. Recent research has highlighted the interactions between tumors and the immune system, pointing towards the potential of bioengineering virus platforms to improve immunotherapy effectiveness.
Selective oncotropism and cytolytic activity against tumors have made certain viruses subject to investigation as novel treatment modalities. However, monotherapy with oncolytic viruses (OVs) has shown limited success and modest clinical benefit. The capacity to genetically engineer OVs makes them a desirable platform to design complementary treatment modalities to overcome the existing treatment options' shortcomings. In recent years, our knowledge of interactions of the tumors with the immune system has expanded profoundly. There is a growing body of literature supporting immunomodulatory roles for OVs. The concept of bioengineering these platforms to induce the desired immune response and complement the current immunotherapeutic modalities to make immune-resistant tumors responsive to immunotherapy is under investigation in preclinical and early clinical trials. This review provides an overview of attempts to optimize oncolytic virotherapy as essential components of the multimodality anticancer therapeutic approach and discusses the challenges in translation to clinical practice. (c) 2021 by American Society of Clinical Oncology (c) 2021 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available